Novel Psilocin Prodrugs with Altered Pharmacological Properties as Candidate Therapies for Treatment-Resistant Anxiety Disorders [ACS Publications]
Monday, January 29, 2024 1 min read
Key Takeaway: Researchers have developed novel psilocin prodrugs aimed at treating treatment-resistant anxiety disorders. These prodrugs maintain the therapeutic benefits of psilocybin while reducing the duration of its psychedelic effects. The study involved synthesizing 28 new chemical entities to achieve altered pharmacokinetic profiles, potentially improving the application of psilocybin therapy.
Price reaction · baseline $161.55 (2024-01-26 close) · hit pre-market · clean, no other ENVB news in the window
day 0 close
+0.3%
Market Sentiment Analysis
POSITIVE FACTORS
Novel prodrugs show potential for treating anxiety disorders.
Reduced duration of psychedelic effects may enhance therapeutic application.
Synthesis of 28 new chemical entities indicates significant research progress.
Full Press Release Details
The psychedelic prodrug psilocybin has shown therapeutic benefits for the treatment of numerous psychiatric conditions. Despite positive clinical end points targeting depression and anxiety, concerns regarding the duration of the psychedelic experience produced by psilocybin, associated with enduring systemic exposure to the active metabolite psilocin, pose a barrier to its therapeutic application. Our objective was to create a novel prodrug of psilocin with similar therapeutic benefits but a reduced duration of psychedelic effects compared with psilocybin. Here, we report the synthesis and functional screening of 28 new chemical entities. Our strategy was to introduce a diversity of cleavable groups at the 4-hydroxy position of the core indole moiety to modulate metabolic processing. We identified several novel prodrugs of psilocin with altered pharmacokinetic profiles and reduced pharmacological exposure compared with psilocybin. These candidate prodrugs have the potential to maintain the long-term benefits of psilocybin therapy while attenuating the duration of psychedelic effects.
Full Publication >>
Frequently Asked Questions
What are psilocin prodrugs?
Psilocin prodrugs are modified forms of psilocin designed to enhance therapeutic effects while reducing psychedelic duration.
How do these prodrugs benefit anxiety treatment?
They maintain the therapeutic benefits of psilocybin but reduce the duration of psychedelic effects, making treatment more manageable.
What was the objective of the research?
The objective was to create psilocin prodrugs with similar benefits to psilocybin but with a shorter psychedelic experience.
How many new chemical entities were synthesized?
The research involved synthesizing 28 new chemical entities to explore their potential as psilocin prodrugs.